CRIS Current Research Information System

PALLONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.599
AS - Asia 4.420
EU - Europa 2.716
AF - Africa 323
Continente sconosciuto - Info sul continente non disponibili 298
SA - Sud America 180
OC - Oceania 5
Totale 12.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.493
VN - Vietnam 1.179
SG - Singapore 1.139
CN - Cina 1.131
IT - Italia 827
GB - Regno Unito 351
SE - Svezia 345
DE - Germania 286
HK - Hong Kong 232
KR - Corea 182
IN - India 172
FR - Francia 148
NL - Olanda 145
IE - Irlanda 123
BR - Brasile 118
CH - Svizzera 117
FI - Finlandia 111
CI - Costa d'Avorio 106
BD - Bangladesh 105
RU - Federazione Russa 84
SC - Seychelles 66
CA - Canada 55
JP - Giappone 52
NG - Nigeria 50
ZA - Sudafrica 43
TG - Togo 40
PH - Filippine 32
ID - Indonesia 29
JO - Giordania 27
AT - Austria 26
BG - Bulgaria 21
TR - Turchia 21
GR - Grecia 20
IQ - Iraq 20
MX - Messico 20
AR - Argentina 18
EE - Estonia 18
UA - Ucraina 17
BE - Belgio 16
TW - Taiwan 16
PK - Pakistan 15
PL - Polonia 15
TH - Thailandia 14
CL - Cile 12
ES - Italia 11
PS - Palestinian Territory 11
SA - Arabia Saudita 10
LT - Lituania 9
EC - Ecuador 8
NI - Nicaragua 8
CR - Costa Rica 6
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
MA - Marocco 5
MY - Malesia 5
PT - Portogallo 5
UZ - Uzbekistan 5
DZ - Algeria 4
HN - Honduras 4
PE - Perù 4
RO - Romania 4
AU - Australia 3
BO - Bolivia 3
DK - Danimarca 3
IR - Iran 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AO - Angola 2
BB - Barbados 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GT - Guatemala 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AZ - Azerbaigian 1
BH - Bahrain 1
CG - Congo 1
CU - Cuba 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
HT - Haiti 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MT - Malta 1
Totale 12.239
Salva come PNG Salva come JPEG
Città #
Singapore 822
Dallas 689
Ashburn 474
Hefei 398
Chandler 318
San Jose 294
Ho Chi Minh City 273
Southend 267
Hanoi 254
Fairfield 224
Hong Kong 217
Boardman 163
Bologna 160
Seoul 160
Santa Clara 142
Houston 131
Beijing 127
Dong Ket 126
Dublin 123
Council Bluffs 115
Bern 107
Abidjan 106
New York 102
Princeton 100
Wilmington 92
Helsinki 89
Seattle 89
Woodbridge 86
Rome 74
Los Angeles 72
Lauterbourg 65
Cambridge 64
Frankfurt am Main 59
Ann Arbor 58
Milan 52
Tokyo 43
Lomé 40
Buffalo 38
Da Nang 38
Bengaluru 35
Turin 35
Berlin 32
Redmond 32
Haiphong 30
Nanjing 29
Redondo Beach 28
Amman 26
London 25
Westminster 25
Abeokuta 24
São Paulo 24
Tongling 24
Munich 22
Sofia 21
Florence 20
Shanghai 20
Jakarta 18
Lappeenranta 18
Toronto 17
Jinan 16
Johannesburg 16
San Diego 16
Biên Hòa 15
Hải Dương 15
Amsterdam 14
Guangzhou 14
Padova 14
Medford 13
Nuremberg 13
Orem 13
Ravenna 13
Brooklyn 12
Brussels 12
Can Tho 12
Hyderabad 12
Phoenix 12
Bến Tre 11
Chicago 11
Montreal 11
Shenyang 11
Thái Nguyên 11
Vienna 11
Denver 10
Des Moines 10
Groningen 10
Istanbul 10
Olalla 10
Warsaw 10
Atlanta 9
Baghdad 9
Chennai 9
Falkenstein 9
Halhul 9
Stockholm 9
Tianjin 9
Wuhan 9
Wuxi 9
Bari 8
Bắc Ninh 8
Managua 8
Totale 7.819
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 470
Adjuvant treatment in biliary tract cancer 347
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 311
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 306
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 305
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 286
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 253
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 248
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 236
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 229
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 224
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 222
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 220
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 220
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 216
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 216
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 210
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 204
Bone metastases in biliary cancers: A multicenter retrospective survey 203
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 199
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 198
In Reply 196
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 195
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 194
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 191
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 191
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 188
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 183
State of the art biological therapies in pancreatic cancer 182
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 181
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 180
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 179
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 177
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 174
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Chemotherapy in Patients with Advanced Cholangiocarcinoma 168
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 165
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 164
Hacking pancreatic cancer: Present and future of personalized medicine 163
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 155
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 154
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 146
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 141
Experimental HER2- targeted therapies for biliary tract cancer 130
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 129
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 127
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 124
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 124
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 122
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 113
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 111
Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma 111
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 108
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma? 106
Nivolumab: an investigational agent for the treatment of biliary tract cancer 103
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 101
Concurrent Chemoradiation Outperforms Chemotherapy Alone in the Treatment of Unresectable Biliary Tract Cancers: A Meta-analysis. 94
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 86
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 80
Does Adjuvant Therapy in Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Improve Survival? A Systematic Review and Meta‐Analysis Using Trial Sequential Analysis 67
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 56
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 44
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 36
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 36
Totale 12.541
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.983
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.983
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022999 0 37 43 75 70 34 26 73 135 113 236 157
2022/20231.407 125 203 71 141 101 101 45 83 224 64 92 157
2023/2024471 76 55 32 42 37 81 20 27 15 37 28 21
2024/20251.888 100 200 163 119 169 73 114 123 61 186 173 407
2025/20265.912 530 626 992 422 475 238 517 197 991 397 239 288
2026/2027236 127 109 0 0 0 0 0 0 0 0 0 0
Totale 12.541